FDA can't guarantee drug safety
The government's own auditor says FDA is failing. Testifying before a Congressional subcommittee yesterday, the director of healthcare for the Government Accountability Office said the agency can't guarantee the safety of the U.S. drug supply because its oversight of foreign drug manufacturers is horribly lax. The agency's record-keeping is so poor, it doesn't even know which facilities haven't been inspected, the GAO rep said.
And at the current rate of inspection, it would take the agency 13 years to examine each facility once--and those are just the factories it knows about. Volunteers often conduct inspections. And the facilities are given advance warning that inspectors are coming. Luckily, U.S. drug makers don't rely on the FDA to ensure its foreign suppliers are delivering quality goods. The companies conduct their own inspections, and they test some shipments to make sure they're OK.
- read the report from the New York Times
Related Articles:
Overseas drugmaking goes unsupervised. Report
Poll finds problems at the FDA. Report
FDA offers safety reforms to skeptical lawmakers. Report
IOM slams FDA, calls for major reforms. Report
Comments
Drugs manufactured in USA territory are safe. Drug manufactured in other places such as Europe,UK Etc. probably not. Duration of FDA inspections outside US territory are three days while in the USA they stay as long as two weeks. Sometimes more. So ask yourself what do you think they can find in three days?? In most of the cases probably nothing.
So you mean it is safe to have people on the advisory board who give recommandations to FDA. The same people are paid by drug companies. Like Paul Offit who are paid by drugkompanies to inject neurotoxins in childrens blodstream. And he denies any sideeffects by injecting MERCURY, ASPARTAM,ALUMINUM and more.
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

